Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.55 |
| ▸ | CA12 | O43570 | 10/20 | 0.55 |
| ▸ | CA1 | P00915 | 10/20 | 0.55 |
| ▸ | CA9 | Q16790 | 10/20 | 0.55 |
| ▸ | CA4 | P22748 | 6/20 | 0.55 |
| ▸ | CA6 | P23280 | 5/20 | 0.55 |
| ▸ | CA5A | P35218 | 5/20 | 0.55 |
| ▸ | CA7 | P43166 | 5/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409435 | 0.82 | CA2 (0.57) | CA2CA12CA1CA9CA4 | |
| SCHEMBL5036445 | 0.82 | HTR2A (0.40) | CA2CA12CA1CA9CA4 | |
| SCHEMBL31726618 | 0.81 | CA2 (0.55) | CA2CA12CA1CA9CA4 | |
| SCHEMBL22792159 | 0.81 | CA2 (0.55) | CA2CA12CA1CA9CA4 | |
| Hydrochloric Acid SCHEMBL23144996 | 0.81 | CA2 (0.55) | CA2CA12CA1CA9CA4 | |
| SCHEMBL29995663 | 0.81 | PIK3CD (0.39) | CA2CA12CA1CA9CA4 | |
| SCHEMBL20489229 | 0.81 | PIK3CD (0.39) | CA2CA12CA1CA9CA4 | |
| SCHEMBL7421043 | 0.78 | CA2 (0.47) | CA2CA12CA1CA9CA4 | |
| SCHEMBL20681235 | 0.77 | CA2 (0.50) | CA2CA12CA1CA9CA4 | |
| SCHEMBL20668119 | 0.77 | CA12 (0.50) | CA2CA12CA1CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121939-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-1149091-B1 | 4-(HETEROCYCLYLSULFONAMIDO)-5-METHOXY-6-(2-METHOXYPHENOXY)-2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-03-19 | — | — | EP | disclosed |
| EP-1149091-A1 | 4-(HETEROCYCLYLSULFONAMIDO)-5-METHOXY-6-(2-METHOXYPHENOXY)-2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6242601-B1 | ENDOTHELIN RECEPTORS INHIBITORS SUCH AS 4-(4-METHOXY-5-(2-METHOXY-PHENOXY)-6-(5-METHYL-PYRIDINE-2-SULF ONYLAMINO)-PYRIMIDIN-2-YL)-PYRIDINE-2-CARBOXYLIC ACID USED TO TREAT CARDIOVASCULAR SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| WO-2000042035-A1 | 4-(HETEROCYCLYLSULFONAMIDO) -5-METHOXY-6- (2-METHOXYPHENOXY) -2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059220-A1 | SUBSTITUTED BENZOTHIOPHENE DERIVATIVES AND METHODS OF USE THEREOF | SULT1E1, TPMT, SULT1A1 | CA2 3804/4885CA12 3290/4885CA1 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.